Background: This study is a retrospective evaluation of patients who were subject to mixing study in our laboratory due to prolonged APTT. The preliminary diagnoses, clinical manifestations, and results of additional ordered tests were reviewed. The study aims to investigate whether repeating APTT test with a different assay prior to performing mixed study in patients with prolonged APTT would be a better alternative algorithmic approach in order to save both time and costs.
Methods:
We retrospectively evaluated 166 patients (65 females and 101 males) who were subject to mixing study due to isolated prolonged APTT. Additional ordered tests to identify the etiology and clinical findings were reviewed. All patients who had prolonged APTT as a result of testing with Hemosil Synthasil APTT reagent in ACL TOP analyzer were repeated with Stago Cephascreen APTT reagent in STA-R coagulation analyzer.
Results:
APTT test was requested preoperatively in 72.2% of cases. Only 6.6% of the cases had history of bleeding. Correction with mixing study was achieved in 122 (73.5%) cases, among which 75 (45%) cases were found to have APTT test results within reference range when tested with Cephascreen reagent. In 44 (26.5%) cases, mixing study did not result in correction. Only 4 cases were confirmed to have lupus anticoagulants (LA), while 4 cases were diagnosed with hemophilia with inhibitors.
Conclusion:
Prolonged APTT results should always be retested using a different assay prior to mixing study. The clinician and the laboratory specialist should collaborate at the postanalytical phase.
K E Y W O R D S
APTT, coagulation, mixing test APTT is not a standardized test, and many limitations to APTT testing exist. Unexpected APTT elevations do not always indicate a pathology. It is not always easy to identify the cause of elevation in APTT, even when there is some clinical background (bleeding or thrombosis). 7 Although the testing is performed in in vitro conditions and free from the influences of molecules and systems playing role in vivo, the test results are used to interpret patient's condition. 3 For instance, despite a lack of clinical bleeding in FXII, prekallikrein or HMWK deficiencies, APTT can be prolonged. Also, sepsis, malignancy, and atherosclerosis are also associated with disturbance in physiological hemostasis and abnormal coagulation test results. [8] [9] [10] [11] These should always be considered when interpreting APTT results.
Another challenging factor for standardization of APTT assays is the content of these assays. APTT reagents have two main components:
an activator (kaolin, celite, silica, polyphenol, ellagic acid, etc.) and a phospholipid source. Activator's role is to provide a negatively charged surface required for activation of the coagulation factors.
Phospholipid content of the reagents is highly variable in terms of both concentration and source. 3, 10 The diversity in concentration The purpose of this study was to retrospectively evaluate patients who were subject to mixing study in our laboratory during the last 1 year due to isolated prolongation APTT, by examining their clinical and laboratory findings, and to investigate whether it would be a better approach to repeat APTT test with a different assay prior to performing mixed study. At the end of the incubation, the tubes were placed on ice to stop the reaction, and APTT was measured using ACL TOP analyser. If the difference in postincubation APTT results between the control tube and the patient tube was >10%, the result was interpreted as inhibitor screening (+), and if the difference was <10%, the result was interpreted as correction achieved.
| MATERIAL AND ME THOD
FVIII, FIX, FXI, and FXII levels were measured using STAdeficient (VIII, IX, XI, and XII) (Diagnostica Stago) reagents with STA-R coagulation analyzer (the reference range was 50% to 150%).
LA test was performed with both LA-sensitive PTT-LA screening reagent and also STA-Staclot dRVV Screen and STA-Staclot dRVV
Confirm reagents on STA-R coagulation analyzer. 13 For those that were suspected to have an inhibitor, inhibitor testing was performed with modified Bethesda assay. In Bethesda assay, titers >0.6 BU/mL were accepted as inhibitor-positive. In all cases using DOACs, mixing study was requested. While mixing study resulted in correction in 6 cases (2 cases had mild FVIII deficiency, 2 cases had FIX deficiency, and 2 cases had FXI deficiency), no correction was achieved in the remaining 14 cases. LA test was requested for all these 14 cases, and 2 cases were found to 
| D ISCUSS I ON
In this study, we examined the records of 166 cases, either inpatient or outpatient, who were subjected to mixing study due to prolonged APTT. None of these cases' preliminary diagnosis or clinical information was conveyed to our laboratory, and additional tests for investigation were requested by the clinician.
Majority of the tests were ordered as part of the routine preoperative work-up. Only 6.6% had history of bleeding, while 3.2% had history of pulmonary embolism or deep vein thrombosis. APTT is not very sensitive in predicting the risk of perioperative bleeding. [2] [3] [4] [5] If there is no history of bleeding or thrombophilia at the preoperative phase, APTT may lead to confusion and result in many unnecessary testing, or unnecessary treatments such as administration of fresh frozen plasma, causing delays in operations.
3-5,10,15
Prolonged APTT does not necessarily indicate a pathology. 10, 15 In our study, no pathology was detected in majority of the cases.
Among 44 cases who did not achieve correction with mixing study, LA testing was requested for 40 cases, of which 6 were found to be LA-positive. Inhibitor assay was requested for 11 cases, and 5 of them were detected to have inhibitor (4 cases had hemophilia with inhibitor). A review of medical files of the 2 LA-positive cases showed that they used DOACs due to atrial fibrillation in one case and cerebrovascular event in the other case. One case who was detected to have low-titer inhibitor was also using DOACs due oral anticoagulant use. However, though it is becoming increasingly common, the impact of DOACs on coagulation tests is not well recognized. 16, 17 As it is seen in our results, almost all cases 12 Although the general conception is that APTT is prolonged when factor levels drop to 30%-50% of normal, 1,4 its sensitivity varies according to assays from different manufacturers or between various reagents produced by the same manufacturer. [19] [20] [21] [22] In our laboratory, we use Hemosil Synthasil APTT reagent. In the present study, prolonged APTT results by Hemosil Synthasil reagent were repeated using Stago Cephascreen APTT reagent with STA-R coagulation analyzer, and 75 cases were found to have normal results in the repeat testing. None of these cases had history of bleeding or thrombosis. Although both reagents contain silica as activator, the composition and source of both silica and phospholipid are different. Although both assays have similar reference ranges, there was significant difference regarding mean APTT results (P < .001).
This difference may have resulted from differences in both reagent sensitivity and the measurement method. Based on our findings, it would be a more effective approach to repeat prolonged APTT test results using a different reagent and measurement method prior to mixing studies, in order to save both time and costs, especially for those cases tested for preoperative screening purposes. As factor 50,00 75,00 100,00 125,00
Stago STA-R MAX levels were not requested in all cases, we could not determine which factors affected our assays.
FXII deficiency is the most common cause of prolonged APTT (responsible for 30%-50%) 1, 4 In our study, FXII deficiency was detected in 2.4% of cases. The reason we had such a low rate may be
because not all cases were tested for FXII level.
There are some limitations to our study. that should follow in the face of abnormal test results. In our study, many tests were requested for no reason, and most possibly, whether these tests were indicated or not were not considered. Another worrying fact is that some of the cases who were subjected to mixing study were not followed up by clinicians. For such cases, possible coagulation disorders may have gone undiagnosed. In our study, thrombin time was not requested in any of the cases to rule out heparin contamination. The laboratory specialist should be authorized to perform reflex test when necessary and should be able to guide the clinician in this respect. Many patients are either tested unnecessarily when there is no need or else not investigated when there is high risk of bleeding and go undiagnosed. The clinician and the laboratory specialist should always collaborate when interpreting the test results or deciding on the selection of additional tests.
In conclusion, rather than functioning as a routine test laboratory, coagulation laboratories should be arranged as coagulation disorders investigation laboratories, and standardization should be achieved in this respect, with collaboration between the clinician and the laboratory specialist.
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